Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01122199 · ClinicalTrials.gov registry record · Phase 1

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

A Phase 1 study, sponsored by Shadia Jalal.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target

NCT01122199: Completed Phase 1 study, sponsored by Shadia Jalal.

NCT01122199 is a Phase 1 study that has completed, run by Shadia Jalal. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01122199, a Phase 1 study, has completed, sponsored by Shadia Jalal.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target

Study Summary

The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.

Interventions

  • DRUG RAD001 + AMG479

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2010-05-14
Est. Completion 2015-01-19
Phase Phase 1
Shadia Jalal

2 total trials

What the finished NCT01122199 record still lists

NCT01122199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).

The record links to 0 conditions, and to 1 intervention - of which RAD001 + AMG479 is the first listed.

NCT01122199 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01122199 about?

NCT01122199 is a clinical study titled "Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors". The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side e...

What is the current status of trial NCT01122199?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-05-14. Estimated completion is 2015-01-19.

What interventions are being tested in trial NCT01122199?

The interventions under investigation include: RAD001 + AMG479 (DRUG).

Who is sponsoring clinical trial NCT01122199?

This trial is sponsored by Shadia Jalal, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01122199's enrollment target sits among peer trials

27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00912041 · 27 participants · NA

    BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

  • NCT02847559 · 27 participants · Phase 2

    Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

  • NCT03380195 · 27 participants · NA

    Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness

  • NCT03384238 · 27 participants · Phase 1

    Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01122199, the US trial registry maintained by the National Library of Medicine. NCT01122199 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.